Mpox Remains a Moderate Health Risk for Certain Men

The World Health Organization (WHO) recently published the 59th situation report for the multi-country outbreak of mpox, which provides details on the global epidemiological situation for mpox.

As of November 2, 2025, the WHO stated all clades of the monkeypox virus (MPXV) continue to circulate across all regions.

In September 2025, 42 countries reported a total of 3,135 confirmed cases, including 12 related fatalities.

More than 80% of these cases were reported in the African Region.

The WHO wrote, 'In light of expanding community transmission of clade Ib MPXV and its detection among men who have sex with men, WHO currently assesses the public health risk as moderate for men who have sex with men and low for the general population in contexts outside historically endemic areas.'

From a prevention perspective, More than 684,000 doses of MVA-BN (JYNNEOS) and 118,000 doses of LC16 have been administered in the Democratic Republic of the Congo, which accounts for more than 61% of people vaccinated in African countries.

Other countries that recently reported mpox are developing national mpox vaccination plans and are encouraged to consider dose-sparing options of the MVA-BN vaccine.

Additional doses have been donated and procured, and partners continue to work together to support access to mpox vaccines and secure operational funds for implementation of national mpox vaccination plans.

In the United States, the JYNNEOS vaccine is offered at various health clinics and pharmacies and is recommended for at-risk individuals.